Zydus Lifesciences Moat Analysis: Score & Risks
Zydus Lifesciences Ltd.
A first-pass moat teardown of Zydus Lifesciences Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.
Zydus Lifesciences Ltd. scores 5.47 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Increase in batch sizes, improvement in the overall equipment efficiency of the packing lines and value stream”
“Launched the first biosimilar of an Antibody Drug Conjugate (ADC) Trastuzumab Emtansine under the brand name UjviraTM in India.”
“We entered into an agreement with CVS Caremark to add ZituvioTM, ZituvimetTM and ZituvimetTM XR tablets to its formulary.”
“The Company is one of the prominent players in the Indian Pharmaceutical Market (IPM) with a strong foothold across multiple therapies and a field force of nearly 5800 people.”
“the USFDA issued an Establishment Inspection Report (EIR) with a VAI status to our transdermal formulation facility located in the Ahmedabad SEZ against an inspection conducted in the month of July, 2024.”
“So, it's still under litigation. So, I think it's very difficult to give any timelines. But as I said, this potentially has the chance to continue for a longer period of time.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion